Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05393180 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CONVERGE Post-Approval Study (PAS)

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Jan 1, 2029 to Nov 21, 2028v14
  2. Study sites: 12 to 13v13
  3. Trial status: Recruiting to Active, Not Recruitingv12 Show 4 more changesShow less
    • Enrollment target: estimated 325 to confirmed 53
    • Study sites: 25 to 12
    • Primary completion date: Nov 1, 2027 to Jan 1, 2027
    • Study completion date: Dec 31, 2028 to Jan 1, 2029
  4. Study sites: 14 to 25v11
  5. Primary completion date: Nov 1, 2025 to Nov 1, 2027
    • Study sites: 9 to 14
    • Study completion date: Dec 31, 2025 to Dec 31, 2028
    v10
Show 8 earlier versionsHide 8 earlier versions
  1. Re-verified, no change to tracked fieldsv9
  2. Site details revised at 1 of 9 sitesv8
  3. Eligibility criteria expanded, about 28 wordsv7
  4. Study sites: 7 to 9v6
  5. Study sites: 5 to 7v5
  6. Study sites: 4 to 5v4
  7. Study sites: 3 to 4v3
  8. Study sites: 2 to 3v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AtriCure, Inc.
9 trials monitored
See 1 trial at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Atrial Fibrillation
1,182 trials monitored
See 50 trials at risk
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Trial Details
NCT Number NCT05393180
Lead Sponsor AtriCure, Inc.
Conditions
(from sponsor)		 Chronic Atrial Fibrillation
Enrollment 53 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov